AU Patent

AU2017279760A1 — Drug substance preparations, pharmaceutical compositions and dosage forms comprising S-(+)-flurbiprofen

Assigned to Aesica Pharmaceuticals Ltd · Expires 2018-02-01 · 8y expired

What this patent protects

Abstract There is described (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid, or a salt or ester thereof, having substantially limited amounts of specific impurities associated with the synthesis and purification of the (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid.

USPTO Abstract

Abstract There is described (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid, or a salt or ester thereof, having substantially limited amounts of specific impurities associated with the synthesis and purification of the (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017279760A1
Jurisdiction
AU
Classification
—
Expires
2018-02-01
Drug substance claim
No
Drug product claim
No
Assignee
Aesica Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.